newsfilter
← Latest News
ACCESS Newswire·

Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete a